SEC Comment Letter for Limitless Venture Group Inc. (CIK 0001794009) — Oct 7, 2021

Limitless Venture Group Inc. (CIK 0001794009)
Date: Oct. 7, 2021 · CIK: 0001794009 · Accession: 0000000000-21-012248

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 024-11128

Date

October 7, 2021

Author

cc: Thomas C. Cook

Form

UPLOAD

Company

Limitless Venture Group Inc. (CIK 0001794009)

Letter

United States securities and exchange commission logo October 7, 2021 Joseph Francella Chief Executive Officer Limitless Venture Group Inc. 121 E 35th Street Tulsa, OK 74106 Re:Limitless Venture Group Inc. Post- Qualification Amendment No. 6 to Form 1-A Filed September 30, 2021 File No. 024-11128 Dear Mr. Francella: This is to advise you that we do not intend to review your amendment. We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Michael Davis at 202-551-4385 with any questions.

Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Thomas C. Cook

Show Raw Text

United States securities and exchange commission logo
October 7, 2021
Joseph Francella
Chief Executive Officer
Limitless Venture Group Inc.
121 E 35th Street
Tulsa, OK 74106
Re:Limitless Venture Group Inc.
Post- Qualification Amendment No. 6 to Form 1-A
Filed September 30, 2021
File No. 024-11128
Dear Mr. Francella:
            This is to advise you that we do not intend to review your amendment.
            We will consider qualifying your offering statement at your request.  If a participant in
your offering is required to clear its compensation arrangements with FINRA, please have
FINRA advise us that it has no objections to the compensation arrangements prior to
qualification.
            We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
            Please contact Michael Davis at 202-551-4385 with any questions.

Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Thomas C. Cook

SecProbe.io